Early Detection Biomarkers for Alzheimer’s: A Clinician’s Guide

By Dr. Gregory C. Fors
Board Certified Chiropractic Neurologist
Chief Science Officer, BioSpec Nutritionals
Pain and Brain Healing Center

Don't wait for Alzheimer's. Find the metabolic and inflammatory changes decades before Alzheimer's develops.

As clinicians, we are often presented with patients at the end-stage of a decades-long pathophysiological process. You do not grow an Alzheimer’s brain in a year. You do not wake up at age 75 and suddenly develop neurodegeneration. In the majority of clinical cases, the process of cognitive decline began twenty or thirty years earlier, often in a patient's forties or fifties.

The tragedy of modern neurology is that many individuals wait until significant memory loss develops before seeking professional help. Unfortunately, by the time memory loss is obvious, the structural and pathological changes may have been occurring for half a lifetime. Waiting for memory loss is waiting too long.

The future of Alzheimer’s prevention lies in identifying risk early and measuring biological dysfunction through specific biomarkers. When we intervene before significant neuronal damage occurs, we transition from reactive care to proactive clinical preservation.

The Metabolic Driver: Insulin Resistance as "Type 3 Diabetes"

If there is one area of functional medicine that is frequently overlooked in the prevention of cognitive decline, it is systemic and central insulin resistance. There is an increasing body of evidence suggesting that insulin resistance is a primary modifiable risk factor for Alzheimer's disease.

Conventional screening frequently misses the early stages of metabolic dysfunction. A patient may present with "normal" fasting blood sugar while significant insulin resistance is already damaging the blood-brain barrier.

Fasting Glucose: Often the Last Marker to Change

One of the most common clinical errors is over-relying on fasting glucose as an early screening tool. Fasting glucose is often the last laboratory marker to become abnormal because the body can compensate for years by increasing insulin output. In other words, a patient may maintain a "normal" fasting glucose while already living in a state of significant hyperinsulinemia and metabolic dysfunction.

This is why a normal fasting glucose does not rule out insulin resistance. It may simply mean the pancreas is still able to keep glucose within range by producing excessive amounts of insulin. By the time fasting glucose begins to rise consistently, the metabolic disturbance has often been present for years and may already be affecting cerebrovascular integrity, inflammatory signaling, and neuronal fuel metabolism.

Fasting Insulin: The Earliest Warning Signal

Fasting insulin is one of the earliest and most clinically useful indicators of emerging metabolic dysfunction. As insulin resistance develops, the pancreas compensates by secreting more insulin in an attempt to keep serum glucose controlled. This compensatory state may persist for years before fasting glucose or A1c becomes overtly abnormal.

Chronically elevated insulin is not benign. It is associated with increased oxidative stress, endothelial dysfunction, neuroinflammation, impaired metabolic flexibility, and disruption of normal brain energy utilization. In the context of Alzheimer's prevention, an elevated fasting insulin may be one of the clearest early signs that a patient is moving toward the terrain often described as "Type 3 diabetes."

• Clinical Target:  5 µIU/mL or less.

Glucose and Insulin Must Be Interpreted Together

Fasting glucose and fasting insulin should be interpreted as a relationship, not as isolated values. Looking at glucose alone can create false reassurance. A patient with a fasting glucose of 90 mg/dL may appear metabolically "normal," but if fasting insulin is elevated, that glucose value is being maintained through compensatory hyperinsulinemia.

This is where the HOMA-IR concept becomes clinically valuable. HOMA-IR helps estimate insulin resistance by evaluating the relationship between fasting glucose and fasting insulin. It provides a more functional view of metabolic stress than glucose alone and can identify deterioration years before standard diabetic thresholds are met.

For clinicians focused on cognitive preservation, this combined interpretation is essential. The question is not simply whether glucose is currently elevated. The question is how much metabolic pressure the body requires to keep glucose controlled.

Hemoglobin A1c: Measuring Glycation, Not Just Average Sugar

Hemoglobin A1c is often described as a three-month average of blood sugar, but that explanation is incomplete. Its deeper significance is that it reflects glycation burden. Glycation occurs when glucose binds to proteins and other structures, forming Advanced Glycation End-products (AGEs). These compounds contribute to oxidative injury, vascular stiffening, inflammatory signaling, and tissue dysfunction.

In the brain, glycation matters because AGEs can damage neurons, glial cells, vascular tissue, and structural proteins. They also contribute to the chronic degenerative environment in which neuroinflammatory and neurodegenerative processes accelerate. From a functional perspective, A1c is therefore not simply about diabetes screening. It is a marker of biochemical wear and tear.

• Clinical Target: Below 5.7%.

Nutritional Biomarkers for Neuronal Resilience

The brain’s metabolic requirements are immense, and specific nutritional deficiencies can accelerate the rate of atrophy, impair mitochondrial function, reduce membrane integrity, and weaken the body's ability to regulate inflammation.

The Omega-3 Index

Omega-3 status has direct implications for membrane fluidity, inflammatory regulation, synaptic function, and neuronal resilience. DHA in particular is a major structural fat in the brain, and inadequate omega-3 status may compromise both neuronal communication and the capacity to control inflammatory cascades.

Most patients test far below an optimal range. A value under 5% is common, but that level is not consistent with robust neuroprotection. Clinically, improving the Omega-3 Index often requires sustained, meaningful intake of EPA and DHA rather than casual supplementation.

• Clinical Target: 8% to 10%.

RBC Magnesium

Magnesium is required for hundreds of enzymatic reactions, including those involved in ATP production, membrane stability, nerve conduction, insulin signaling, and vascular tone. In neurological and metabolic care, magnesium status matters far more than many routine panels suggest.

Serum magnesium is often misleading because the body works hard to maintain blood levels within a narrow range, even when intracellular stores are depleted. As a result, a patient can have a "normal" serum magnesium and still be functionally deficient. RBC magnesium is far more informative because it provides a better view of intracellular status, where magnesium is actually doing its work.

This distinction matters in patients with fatigue, headaches, poor stress tolerance, insomnia, constipation, insulin resistance, arrhythmia risk, or neurological irritability. In many cases, intracellular magnesium depletion is clinically significant long before serum values shift.

Vitamin D

Vitamin D acts more like a neuro-immuno-endocrine regulator than a simple vitamin. It influences immune balance, inflammatory tone, neuroprotection, mitochondrial function, and gene expression. Low vitamin D status has been associated with increased risk for cognitive decline, immune dysregulation, low mood, and impaired resilience.

Because many patients spend limited time in the sun and often have impaired absorption or increased physiological demand, suboptimal levels are common.

• Clinical Target: 60 to 80 ng/mL.

Vitamin B12

Vitamin B12 is essential for methylation, myelin integrity, red blood cell formation, and proper neurological function. A patient may have a laboratory value that technically falls within range and still experience functional insufficiency, particularly if neurological symptoms, macrocytosis, fatigue, cognitive changes, or elevated homocysteine are present.

For clinicians, B12 should not be viewed in isolation. It is part of a larger neurological and methylation picture that must be interpreted alongside folate, homocysteine, red cell markers, symptoms, medications, and digestive function.

Folate

Folate plays a central role in one-carbon metabolism, methylation, DNA repair, and homocysteine regulation. In the context of brain health, folate status matters because methylation is deeply involved in neurotransmitter balance, membrane maintenance, detoxification, and genomic stability.

As with B12, the issue is not merely whether folate is technically in range, but whether the methylation network is functioning adequately in the real patient in front of you.

Homocysteine and Methylation

Homocysteine is one of the most clinically valuable functional biomarkers in preventive medicine. Elevated homocysteine is associated with impaired methylation, vascular injury, oxidative stress, endothelial dysfunction, and increased neurodegenerative risk. It is not simply a cardiovascular marker. It is also a brain-aging marker.

Many conventional laboratories report values up to 15 µmol/L as "normal," but that threshold is far too permissive if the goal is long-term neurological preservation. A patient can be told everything is fine while still carrying a level of vascular and neurological risk that deserves intervention. In a more optimal clinical model, we aim for a narrower and more protective range.

• Clinical Target: 5.2 to 7.4 µmol/L.

Inflammatory Biomarkers: Measuring the Terrain

Healthy neurons require a stable internal environment. Persistent inflammation alters vascular function, disrupts insulin signaling, impairs glymphatic clearance, and creates the biochemical terrain in which neurodegeneration becomes more likely.

High-Sensitivity C-Reactive Protein (hs-CRP)

hs-CRP is one of the most practical markers for identifying low-grade systemic inflammation. Even modest elevations may indicate that inflammatory signaling is active enough to influence vascular health, oxidative burden, and neurodegenerative risk. Inflammation is one of the major forces that accelerates protein misfolding, endothelial injury, and metabolic breakdown.

• Clinical Target: 1.0 mg/L or less.

Erythrocyte Sedimentation Rate (ESR)

ESR is a broader, less specific inflammatory marker, but it can still add useful context. When elevated, it may reflect a background burden of inflammatory activity that warrants deeper investigation. In the right clinical setting, ESR helps confirm that the body is operating in a more activated inflammatory state than symptoms alone may reveal.

Fibrinogen

Fibrinogen is both a coagulation marker and an inflammatory marker. Elevated fibrinogen suggests a more pro-thrombotic, more inflammatory terrain and may raise concern about microvascular compromise. For the brain, this matters because even subtle impairment in cerebral circulation can influence oxygen delivery, nutrient transport, waste clearance, and long-term tissue resilience.

Cardiovascular Biomarkers: Protecting the Cerebral Vasculature

Healthy cognition depends on healthy blood flow. Anything that impairs vascular integrity, increases atherogenic particle burden, or worsens microcirculatory function can eventually affect the brain.

Apolipoprotein B (ApoB)

ApoB is one of the most important cardiovascular markers available because it reflects the number of atherogenic lipoprotein particles rather than simply the cholesterol content they carry. In many patients, ApoB provides a more accurate estimate of vascular risk than LDL-C alone.

For brain health, this distinction matters. The cerebral vasculature is delicate, and excess atherogenic particle burden contributes to endothelial injury, impaired perfusion, and the long-term conditions that support cognitive decline.

• Clinical Target: Below 90 mg/dL.

Lipoprotein(a) [Lp(a)]

Lp(a) is a genetically influenced cardiovascular risk marker that can materially increase atherosclerotic and thrombotic risk even in patients who otherwise appear metabolically reasonable on a basic lipid panel. It is particularly useful when family history suggests premature cardiovascular disease or when risk seems disproportionate to conventional markers.

Triglycerides

Triglycerides are an important reflection of metabolic health, insulin sensitivity, and hepatic handling of energy. Elevated triglycerides frequently travel with hyperinsulinemia, poor carbohydrate tolerance, fatty liver tendencies, and increased cardiometabolic risk. In a brain-protective model, triglycerides should not be dismissed as a secondary lipid marker.

• Clinical Target: 150 mg/dL or less.

HDL

HDL remains useful when interpreted in context. Low HDL may reflect poor metabolic health, insufficient exercise adaptation, inflammatory burden, insulin resistance, or impaired lipid transport. As with all lipid markers, it should be interpreted as part of a pattern rather than as a standalone hero number.

The New Frontier: Blood-Based Alzheimer’s Biomarkers

One of the most exciting shifts in clinical practice is the emergence of blood-based biomarkers that correlate with traditional (and expensive) PET scans or invasive CSF analysis.

1. Plasma p-Tau217: Currently one of the most promising markers for identifying tau-related pathology and staging disease years in advance.
2. Plasma p-Tau181: An additional marker of neurodegeneration and tau pathology.
3. Beta-Amyloid 42/40 Ratio: Provides insight into amyloid deposition occurring in the brain.
4. Neurofilament Light Chain (NfL): A non-specific but sensitive marker of neuronal injury and axonal damage.
5. APOE Genotyping: Useful for evaluating inherited susceptibility and stratifying long-term risk, but genes are not destiny. APOE status helps define a patient's terrain and tendencies, not an unavoidable future.

These advanced biomarkers are powerful, but they still require context. They are best used as part of a broader clinical picture that includes metabolic, inflammatory, vascular, nutritional, cognitive, and family-history data.

What These Tests Can Tell Us

These biomarkers can help us identify patterns of vulnerability long before overt cognitive decline becomes undeniable. They can reveal early insulin resistance, glycation burden, inflammatory activation, vascular risk, nutritional insufficiency, methylation strain, and signals suggestive of developing neurodegenerative pathology.

They can also help clinicians:

• Stratify risk more intelligently
• Identify modifiable drivers earlier
• Personalize intervention priorities
• Track response over time
• Move from reactive management toward preventive strategy

In other words, biomarkers can provide meaningful clues about where dysfunction is developing and how aggressively we should intervene.

What These Tests Cannot Tell Us

Biomarkers do not provide certainty. They do not diagnose a person's future with absolute precision, and they do not replace clinical judgment. An abnormal result may indicate increased probability, increased vulnerability, or a need for closer investigation, but it is not a prophecy.

Likewise, a favorable lab value does not guarantee protection if symptoms, imaging, history, cognitive changes, or other elements of the case suggest otherwise. These tests must always be interpreted in combination with a full clinical evaluation, patient history, symptom pattern, physical findings, and—when appropriate—additional imaging or specialty testing.

They are tools. They are not the entire story.

Implementing a Biomarker-Led Practice

For practitioners, the goal is not merely collecting numbers, but understanding the entire metabolic and physiological landscape of the patient. When we see a patient complaining of "brain fog," difficulty finding words, or chronic anxiety, these are often the clinical manifestations of the biomarkers listed above.

A Clinical Framework for Practitioners:

• Metabolic Assessment: Prioritize fasting glucose, fasting insulin, and HOMA-IR to identify "Type 3 Diabetes" physiology early.
• Nutritional Optimization: Correct deficiencies and insufficiencies identified through Omega-3 Index, RBC magnesium, vitamin D, B12, folate, and homocysteine.
• Inflammatory Reduction: Use hs-CRP, ESR, and fibrinogen to gauge inflammatory burden and guide intervention intensity.
• Vascular Protection: Manage ApoB, Lp(a), triglycerides, and HDL to preserve cerebral perfusion and vascular resilience.
• Advanced Risk Assessment: Incorporate p-Tau217, p-Tau181, Beta-Amyloid 42/40 Ratio, NfL, and APOE status when clinically appropriate.

By the time a patient presents with memory loss, the window for primary prevention has often closed. By utilizing these biomarkers in our standard workups for patients in their 40s and 50s, we can identify patterns of risk and intervene decades before the diagnosis of Alzheimer's becomes inevitable.

BioSpec Nutritionals provides evidence-based, clinically impactful nutritional supplements designed specifically for healthcare practitioners who demand high-purity, physician-grade solutions for their patients.

Biospec Nutritionals — Medical & Educational Disclaimer
This content is provided for educational and informational purposes only and is not intended to provide medical advice, diagnosis, or treatment. It is not a substitute for individualized guidance from a qualified healthcare professional. Always consult your physician or other qualified healthcare provider before starting, stopping, or changing any supplement, medication, diet, or exercise program.
† FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.